JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

September 24, 2020

Company continues to make progress on its potential treatment for PAD, a disease affecting 200 million people worldwide LAS VEGAS, NV Sept. 24, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production... READ MORE

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

September 22, 2020

Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA’s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions LAS VEGAS, NV Sept. 23, 2020 – JanOne Inc. (Nasdaq:... READ MORE

JanOne Announces Strategic Plan to Divest its Legacy Businesses

September 16, 2020

Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, NV, Sept. 16, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives to... READ MORE

JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials

September 3, 2020

Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, NV Sept. 3, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its... READ MORE

JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials

August 28, 2020

Partnership to ensure clinical compliance for active and placebo dosing for PAD phase 2b trials planned for early 2021 and potential trials for treating Covid-19 vascular complications LAS VEGAS, NV Aug. 28, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving... READ MORE

JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness

August 26, 2020

Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days LAS VEGAS, NV Aug. 26, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch of JAN101.... READ MORE

JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications

August 21, 2020

-Introduction to JanOne scientific team -Strategy for upcoming planned Phase 2b trial of JAN101 -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities LAS VEGAS, Aug. 21, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive,... READ MORE

JanOne to Present at The LD 500 Virtual Conference

August 19, 2020

Presentation to include recent and upcoming developments and overview of drug candidate JAN101 for the potential treatment of peripheral artery disease (PAD) as well as potential applications for COVID-19 vascular complications and planned IND submission process with FDA. Las Vegas, Aug. 19, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments to... READ MORE

JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials

August 11, 2020

JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation LAS VEGAS, Aug. 11, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, has successfully... READ MORE